Fusidic Acid
Các tên gọi khác (6
) :
- Fucidate
- Fucidin acid
- Fusidate
- Fusidic acid
- Fusidine
- Ramycin
Thuốc điều trị bệnh da liễu
Thuốc Gốc
Small Molecule
CAS: 6990-06-3
ATC: D09AA02, D06AX01, S01AA13, J01XC01
CTHH: C31H48O6
PTK: 516.7092
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
Phân tử khối
516.7092
Monoisotopic mass
516.345089268
InChI
InChI=1S/C31H48O6/c1-17(2)9-8-10-20(28(35)36)26-22-15-24(34)27-29(5)13-12-23(33)18(3)21(29)11-14-30(27,6)31(22,7)16-25(26)37-19(4)32/h9,18,21-25,27,33-34H,8,10-16H2,1-7H3,(H,35,36)/b26-20-/t18-,21-,22-,23+,24+,25-,27-,29-,30-,31-/m0/s1
InChI Key
InChIKey=IECPWNUMDGFDKC-MZJAQBGESA-N
IUPAC Name
2-[(1S,2S,5R,6S,7S,10S,11S,13S,14Z,15R,17R)-13-(acetyloxy)-5,17-dihydroxy-2,6,10,11-tetramethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-ylidene]-6-methylhept-5-enoic acid
Traditional IUPAC Name
fusidic acid
SMILES
O[C@@H]1CC[C@@]2(C)[C@@]([H])(CC[C@@]3(C)[C@@]2([H])[C@H](O)C[C@@]2([H])\C([C@@H](OC(=O)C)C[C@]32C)=C(/CCC=C(C)C)C(O)=O)[C@@H]1C
Độ tan chảy
192.5 °C
Độ hòa tan
5.21e-03 g/l
logP
4.42
logS
-5
pKa (strongest acidic)
4.66
pKa (Strongest Basic)
-0.2
PSA
104.06 Å2
Refractivity
144.12 m3·mol-1
Polarizability
59.77 Å3
Rotatable Bond Count
6
H Bond Acceptor Count
5
H Bond Donor Count
3
Physiological Charge
-1
Number of Rings
4
Bioavailability
1
MDDR-Like Rule
true
pKa
5.35
Dược Lực Học :
Cơ Chế Tác Dụng :
Dược Động Học :
Sodium fusidic acid tablets have a 91% oral bioavailability. Absorption of the film-coated tablets is complete when compared to a solution, however oral absorption is variable. Oral fusidic acid hemihydrate (suspension) achieved a 22.5% bioavailability in pediatric patients following a 20 milligram/kilogram dose.
▧ Protein binding :
97 to 99%
▧ Metabolism :
Metabolites include dicarboxylic ester/acid, 3-keto fusidic acid, hydroxy fusidic acid, glucuronide fusidic acid and a glycol metabolite.
▧ Half Life :
Approximately 5 to 6 hours in adults.
Chỉ Định :
Tương Tác Thuốc :
- Amprenavir The protease inhibitor, amprenavir, may increase the effect and toxicity of fusidic acid.
- Atorvastatin Increased risk of myopathy/rhabdomyolysis
- Fosamprenavir The protease inhibitor, fosamprenavir, may increase the effect and toxicity of fusidic acid.
- Indinavir Indinavir may increase the effect and toxicity of fusidic acid.
- Nelfinavir The protease inhibitor, nelfinavir, may increase the effect and toxicity of fusidic acid.
- Penicillin V Fusidic acid may diminish the therapeutic effect of penicillins. To management this interaction, penicillin should be administered 2 hours before fusidic acid.
- Ritonavir The protease inhibitor, ritonavir, may increase the effect and toxicity of fusidic acid.
- Saquinavir The protease inhibitor, saquinavir, may increase the effect and toxicity of fusidic acid.
- Simvastatin Increased risk of myopathy/rhabdomyolysis
- Ticarcillin Fusidic acid may reduce the effect of Ticarcillin by inhibiting bacterial growth. Ticarcillin exerts its effects on actively growing bacteria. To achieve synergism, Ticarcillin should be administered at least 2 hours prior to using Fusidic acid.
- Tipranavir Concomitant therapy of Tipranavir with Fusidic acid may result in increased serum concentrations of both agents. Consider alternate therapy or monitor for increased serum concentrations and toxocity of both agents.
Dữ Kiện Thương Mại
Giá thị trường
-
Biệt dược thương mại : Fucidin 2 % CreamGiá bán buôn : USD >0.66Đơn vị tính : g
-
Biệt dược thương mại : Fucidin 2 % OintmentGiá bán buôn : USD >0.66Đơn vị tính : g
Tài Liệu Tham Khảo Thêm
drugbank
PubChem Compound
PubChem Substance
KEGG Compound
Bạn thấy hài lòng ?
Bạn chưa hài lòng ?
... loading
... loading